EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis

An Lu, Zhiyi Xu, Zhixia Zhao, Yi Yan, Linxia Jiang, Jing Geng, Hongwei Jin, Xiangyu Wang, Xiaoyan Liu, Yuanjun Zhu, Yujie Shi, Lihong Liu und 2 weitere

Advanced Science · 2024-12 · 11 (47)

DOI: 10.1002/advs.202405406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.10.2024. Verfasst von An Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Phar…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Mitochondrial Permeability Transition Pore, Disease Models, Animal, Nanomedicine. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial permeability transition pore (mPTP) opening is a key hallmark of injured type II alveolar epithelial cells (AECIIs) in idiopathic pulmonary fibrosis (IPF). Inhibiting mPTP opening in AECIIs is considered a potential IPF treatment. Herein, a “double braking” strategy on mPTP by cyclosporin A (CsA) derived ionizable lipid with 3D structure (3D‐lipid) binding cyclophilin D (CypD) and siRNA downregulating mitochondrial calcium uniporter (MCU) expression is proposed for treating IPF. 3D‐lipid and MCU targeting siRNA (siMCU) are co‐assembled to form stable 3D‐LNP/siMCU nanoparticles (NPs), along with helper lipids. In vitro results demonstrated that these NPs effectively inhibit mPTP opening by 3D‐lipid binding with CypD and siRNA downregulating MCU expression, thereby decreasing damage‐associated molecular patterns (DAMPs) release and suppressing epithelial‐to‐mesenchymal transition (EMT) process in bleomycin‐induced A549 cells. In vivo results revealed that 3D‐LNP/siMCU NPs effectively ameliorated collagen deposition, pro‐fibrotic factors secretion, and fibroblast activation in bleomycin‐induced pulmonary fibrosis (PF) mouse models. Moreover, compared to the commercial MC3‐based formulation, optimized Opt‐MC3/siRNA NPs with incorporating 3D‐lipid as the fifth component, showed superior therapeutic efficacy against PF due to their enhanced stability and higher gene silencing efficiency. Overall, the nanomedicine containing 3D‐lipid and siMCU will be a promising and potential approach for IPF treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisMitochondrial Permeability Transition PoreDisease Models, AnimalNanomedicineAnimalsMiceHumansMitochondrial Membrane Transport ProteinsNanoparticlesRNA, Small InterferingBleomycinCyclosporineEpithelial-Mesenchymal TransitionA549 CellsCalcium ChannelsMale

Stichwörter der Autor:innen

cyclosporin Aidiopathic pulmonary fibrosisionizable lipidlipid nanoparticlesiRNA delivery

Substanzen

Mitochondrial Permeability Transition PoreMitochondrial Membrane Transport ProteinsRNA, Small InterferingBleomycinCyclosporinemitochondrial calcium uniporterCalcium Channels

Autor:innen und Institutionen

  • Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
  • Department of Pharmacy, Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, 100029, China.
  • National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
  • Laboratory of Innovative Formulations and Pharmaceutical Excipients, Peking University Ningbo Institute of Marine Medicine, Ningbo, 315832, China.

ORCID-Profile: Jian-Cheng Wang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • Ningbo Science and Technology Plan Project
  • Peking University
  • CAMS Innovation Fund for Medical Sciences
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Lu, A., Xu, Z., Zhao, Z., Yan, Y., Jiang, L., Geng, J., Jin, H., Wang, X., Liu, X., Zhu, Y., Shi, Y., Liu, L., Dai, H., & Wang, J. C. (2024). Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis. Advanced Science, 11(47). https://doi.org/10.1002/advs.202405406

Vancouver

Lu A, Xu Z, Zhao Z, Yan Y, Jiang L, Geng J, et al. Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis. Advanced Science. 2024;11(47). doi:10.1002/advs.202405406

BibTeX
@article{Lu2024,
  author = {Lu, An and Xu, Zhiyi and Zhao, Zhixia and Yan, Yi and Jiang, Linxia and Geng, Jing and Jin, Hongwei and Wang, Xiangyu and Liu, Xiaoyan and Zhu, Yuanjun and Shi, Yujie and Liu, Lihong and Dai, Huaping and Wang, Jian-Cheng},
  title = {Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {47},
  doi = {10.1002/advs.202405406}
}
Kostenlos starten →